Literature DB >> 21289515

von Willebrand disease.

Paula D James1, Anne C Goodeve.   

Abstract

von Willebrand disease is a common inherited bleeding disorder characterized by excessive mucocutaneous bleeding. Characteristic bleeding symptoms include epistaxis, easy bruising, oral cavity bleeding, menorrhagia, bleeding after dental extraction, surgery, and/or childbirth, and in severe cases, bleeding into joints and soft tissues. There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants: (1) type 2A-characterized by defective von Willebrand factor-dependent platelet adhesion because of decreased high-molecular-weight von Willebrand factor multimers, (2) type 2B-caused by pathologically increased von Willebrand factor-platelet interactions, (3) type 2M-caused by decreased von Willebrand factor-platelet interactions not based on the loss of high-molecular-weight multimers, and (4) type 2N-characterized by reduced binding of von Willebrand factor to factor VIII. The diagnosis of von Willebrand disease requires specialized assays of von Willebrand factor and/or molecular genetic testing of von Willebrand factor. Severe bleeding episodes can be prevented or controlled with intravenous infusions of virally inactivated plasma-derived clotting factor concentrates containing both von Willebrand factor and factor VIII. Depending on the von Willebrand disease type, mild bleeding episodes usually respond to intravenous or subcutaneous treatment with desmopressin, a vasopressin analog. Other treatments that can reduce symptoms include fibrinolytic inhibitors and hormones for menorrhagia.

Entities:  

Mesh:

Year:  2011        PMID: 21289515      PMCID: PMC3832952          DOI: 10.1097/GIM.0b013e3182035931

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  102 in total

Review 1.  Women and von Willebrand disease: controversies in diagnosis and management.

Authors:  Rezan A Kadir; Claudia Chi
Journal:  Semin Thromb Hemost       Date:  2006-09       Impact factor: 4.180

2.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Authors:  Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges Rivard; Dilys Rapson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

3.  Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques.

Authors:  Mohammad Hashemi Soteh; Ian R Peake; Luke Marsden; John Anson; Javier Batlle; Dominique Meyer; Edith Fressinaud; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Anne Goodeve
Journal:  Haematologica       Date:  2007-04       Impact factor: 9.941

4.  Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

Authors:  J Eikenboom; L Hilbert; A S Ribba; A Hommais; D Habart; S Messenger; A Al-Buhairan; A Guilliatt; W Lester; C Mazurier; D Meyer; E Fressinaud; U Budde; K Will; R Schneppenheim; T Obser; O Marggraf; E Eckert; G Castaman; F Rodeghiero; A B Federici; J Batlle; J Goudemand; J Ingerslev; S Lethagen; F Hill; I Peake; A Goodeve
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

Review 5.  Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease.

Authors:  D Meyer; E Fressinaud; C Gaucher; J M Lavergne; L Hilbert; A S Ribba; S Jorieux; C Mazurier
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

Review 6.  Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.

Authors:  Augusto B Federici
Journal:  Semin Hematol       Date:  2006-01       Impact factor: 3.851

Review 7.  Bleeding disorders in premenopausal women: (another) public health crisis for hematology?

Authors:  Andra H James; Margaret V Ragni; Vincent J Picozzi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

8.  Gynaecological and obstetric management of women with inherited bleeding disorders.

Authors:  Christine Demers; Christine Derzko; Michèle David; Joanne Douglas
Journal:  J Obstet Gynaecol Can       Date:  2005-07

Review 9.  von Willebrand factor and von Willebrand disease.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

Review 10.  Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin.

Authors:  F Rodeghiero
Journal:  Haemophilia       Date:  2008-01       Impact factor: 4.287

View more
  24 in total

1.  An international survey to inform priorities for new guidelines on von Willebrand disease.

Authors:  Mohamad A Kalot; Mohammed Al-Khatib; Nathan T Connell; Veronica Flood; Romina Brignardello-Petersen; Paula James; Reem A Mustafa
Journal:  Haemophilia       Date:  2019-11-26       Impact factor: 4.287

Review 2.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

Review 3.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 4.  Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy.

Authors:  Ozlem Turan; Rezan Abdul Kadir
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

5.  Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease.

Authors:  Hamideh Yadegari; Julia Driesen; Anna Pavlova; Arijit Biswas; Vytautas Ivaskevicius; Robert Klamroth; Johannes Oldenburg
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

6.  Intron retention resulting from a silent mutation in the VWF gene that structurally influences the 5' splice site.

Authors:  Hamideh Yadegari; Arijit Biswas; Mohammad Suhail Akhter; Julia Driesen; Vytautas Ivaskevicius; Natascha Marquardt; Johannes Oldenburg
Journal:  Blood       Date:  2016-08-19       Impact factor: 22.113

Review 7.  Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience.

Authors:  Thuy Tran; Justin Arnall; Donald C Moore; Leslie Ward; Surabhi Palkimas; Louise Man
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

8.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

9.  A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.

Authors:  Ilenia Simeoni; Jonathan C Stephens; Fengyuan Hu; Sri V V Deevi; Karyn Megy; Tadbir K Bariana; Claire Lentaigne; Sol Schulman; Suthesh Sivapalaratnam; Minka J A Vries; Sarah K Westbury; Daniel Greene; Sofia Papadia; Marie-Christine Alessi; Antony P Attwood; Matthias Ballmaier; Gareth Baynam; Emilse Bermejo; Marta Bertoli; Paul F Bray; Loredana Bury; Marco Cattaneo; Peter Collins; Louise C Daugherty; Rémi Favier; Deborah L French; Bruce Furie; Michael Gattens; Manuela Germeshausen; Cedric Ghevaert; Anne C Goodeve; Jose A Guerrero; Daniel J Hampshire; Daniel P Hart; Johan W M Heemskerk; Yvonne M C Henskens; Marian Hill; Nancy Hogg; Jennifer D Jolley; Walter H Kahr; Anne M Kelly; Ron Kerr; Myrto Kostadima; Shinji Kunishima; Michele P Lambert; Ri Liesner; José A López; Rutendo P Mapeta; Mary Mathias; Carolyn M Millar; Amit Nathwani; Marguerite Neerman-Arbez; Alan T Nurden; Paquita Nurden; Maha Othman; Kathelijne Peerlinck; David J Perry; Pawan Poudel; Pieter Reitsma; Matthew T Rondina; Peter A Smethurst; William Stevenson; Artur Szkotak; Salih Tuna; Christel van Geet; Deborah Whitehorn; David A Wilcox; Bin Zhang; Shoshana Revel-Vilk; Paolo Gresele; Daniel B Bellissimo; Christopher J Penkett; Michael A Laffan; Andrew D Mumford; Augusto Rendon; Keith Gomez; Kathleen Freson; Willem H Ouwehand; Ernest Turro
Journal:  Blood       Date:  2016-04-15       Impact factor: 25.476

10.  Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding.

Authors:  Paola E J van der Meijden; Annemieke C Bouman; Marion A H Feijge; René van Oerle; Henri M H Spronk; Karly Hamulyák; Arina J ten Cate-Hoek; Hugo ten Cate; Johan W M Heemskerk
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.